Contact Us Site Map Request More Info
 
About OKTO   Eye Care Professionals   Patients   News and Press
Home     News and Press
Full Listing
Archive


 


OKTO Ophtho Expands Alliance with IOP, Inc. With Distribution of AmbioDry™ Technology

COSTA MESA, California – 22 January 2004 – OKTO Ophtho, the innovation-driven developer of specialty technologies for eye surgery, announced that, beginning 1 March 2004, the Company will exclusively distribute its AmbioDry™ Amniotic Membrane technology through it ongoing commercialization alliance with IOP, Inc. (Innovative Ophthalmic Products, Inc. – Costa Mesa, CA USA).

IOP, Inc., founded in 1988, is focused on the commercialization and distribution of advanced surgical technologies for eye surgery. With its 16-year history in the ophthalmic market, IOP, Inc. has leadership positions with bioimplants and devices for ophthalmic plastic and reconstructive surgeries; glaucoma implant drainage technology; and bioimplants for general ophthalmic surgeries.

Commercially introduced by OKTO to the worldwide ophthalmic market in October 2002, AmbioDry Allografts are processed tissue grafts derived from human placenta and employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. AmbioDry Allografts are procured and processed in the United States.

“Our alliance with IOP for the commercialization and distribution of AmbioDry™ technology is perfect - and will undoubtedly optimize our marketing and sales aims”, stated Erich Ziegler, OKTO’s President. “OKTO made significant progress in 2003 distribution and has positioned AmbioDry™ as the leading amniotic membrane technology for eye surgery. IOP’s resources, industry reputation and complimentary technology lines will accelerate our growth and momentum in the marketplace during 2004 and beyond.”

The OKTO-IOP alliance initially began in 2000 through an agreement for the distribution of the SutureGroove Gold Eyelid Weights – a surgical device employed by oculoplastic surgeons for the treatment of lagophthalmos. The proprietary SutureGroove technology, licensed by OKTO from Advanced Meditech International (AMI), incorporates suture fixation channels within the gold weight for perfected implant placement and improved patient cosmesis.

About OKTO

Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.

Media Contact:

pr@oktoophtho.com